These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 39122830)
1. Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway. Xie S; Liu H; Zhu S; Chen Z; Wang R; Zhang W; Xian H; Xiang R; Xia X; Sun Y; Long J; Wang Y; Wang M; Wang Y; Yu Y; Huang Z; Lu C; Xu Z; Liu H Cancer Gene Ther; 2024 Oct; 31(10):1486-1497. PubMed ID: 39122830 [TBL] [Abstract][Full Text] [Related]
2. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα. Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia. Jebanesan DZP; Illangeswaran RSS; Rajamani BM; Vidhyadharan RT; Das S; Bijukumar NK; Balakrishnan B; Mathews V; Velayudhan SR; Balasubramanian P Ann Hematol; 2024 Jun; 103(6):1919-1929. PubMed ID: 38630133 [TBL] [Abstract][Full Text] [Related]
4. Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells. Yu S; Ge Z; Chen W; Han J Comb Chem High Throughput Screen; 2023; 26(11):2067-2076. PubMed ID: 36694317 [TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells. Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Wang R; Xia L; Gabrilove J; Waxman S; Jing Y Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450 [TBL] [Abstract][Full Text] [Related]
7. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482 [TBL] [Abstract][Full Text] [Related]
10. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. Tan M; Zhang Q; Yuan X; Chen Y; Wu Y J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide. Wang Z; Fang Z; Lu R; Zhao H; Gong T; Liu D; Hong L; Ma J; Zhang M Oncol Res; 2019 Sep; 27(9):1035-1042. PubMed ID: 30982490 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias. Yousefnia S Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587 [TBL] [Abstract][Full Text] [Related]
14. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. Wang QQ; Hua HY; Naranmandura H; Zhu HH Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440 [TBL] [Abstract][Full Text] [Related]
15. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species. Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499 [TBL] [Abstract][Full Text] [Related]
16. The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation. Dembitz V; Lalic H; Ostojic A; Vrhovac R; Banfic H; Visnjic D Int J Hematol; 2015 Jul; 102(1):12-24. PubMed ID: 25758096 [TBL] [Abstract][Full Text] [Related]
17. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001 [TBL] [Abstract][Full Text] [Related]
18. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells. Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967 [TBL] [Abstract][Full Text] [Related]
19. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580 [TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]